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In this issue of Cell Stem Cell, Eiges et al. (2007) generate a human ES cell line from an embryo iden-
tified by preimplantation genetic diagnosis, and shed light on the molecular pathology of fragile X
syndrome. The discovery that, upon differentiation, epigenetic modifications likely trigger silencing
of the FMR1 gene sets the stage for further studies.Fragile X syndrome is a common form
of developmental delay and is among
the best-characterized forms of aut-
ism spectrum disorder (Penagarikano
et al., 2007). Fragile X syndrome dis-
plays a number of unusual features,
such as increased penetrance of the
mutant allele as it is passed through
subsequent generations. Akin to ge-
netic anticipation, where disease se-
verity increases or age of onset dimin-
ishes, fragile X syndrome was among
the first trinucleotide disorders de-
scribed where variation in penetrance
or expressivity increases with meiotic
instability increasing the length of
triplet repeats buried within genes.
With fragile X syndrome, a CGG repeat
is found within the 50 untranslated re-
gion of the FMR1 gene and expands
from an average normal allele length
of 30 triplets to well over 200 repeats
in patients with fragile X syndrome. At
this threshold of about 200 repeats, re-
ferred to as the ‘‘full mutation,’’ a re-
markable phenomenon occurs where
the FMR1 gene itself becomes heavily
CpG methylated and shifts chromatin
marks from a euchromatic state to
a fully heterochromatic state (Coffee
et al., 2002). The result is the transcrip-
tional silencing of FMR1 and the ab-
sence of the encoded protein, FMRP,
leading to the clinical picture of fragile
X syndrome.
While a great deal has been learned
about the pathophysiology of fragile X
syndrome in the past 16 years since
the discovery of the FMR1 gene, one
major enigma remains—the mecha-
nism by which a local epigenetic switch
occurs in response to the expanded
CGG repeat. The difficulty in studying488 Cell Stem Cell 1, November 2007 ª2this unique biological phenomenon is
the absence of suitable material for
study. Methylation of the expanded
FMR1 CGG repeat occurs early in de-
velopment and is a dynamic process.
For example, in early germ cells from
human full-mutation fetuses, the FMR1
repeat is fully expanded and unmethy-
lated (Malter et al., 1997), whereas in
chorionic villus samples from full-mu-
tation fetuses, the expanded repeat is
methylated to an increasing degree
as development progresses (Sutcliffe
et al., 1992). However, these human
tissues are not amenable to experi-
mental manipulation. Moreover, FMR1
epigenetic change appears human
specific, as mouse models bearing
lengthy repeats knocked in to the en-
dogenous Fmr1 gene do not trigger
the epimark. This situation is now
changed with the work of Eiges and
coworkers published in this issue of
Cell Stem Cell (Eiges et al., 2007). Fol-
lowing in vitro fertilization treatment
of a woman carrying 170 CGG re-
peats (the ‘‘premutation’’ carrier state),
preimplantation genetic diagnosis of
12 embryos identified five as normal
(which were subsequently reim-
planted) and seven embryos carrying
the abnormal maternal FMR1 allele.
With these spare embryos, Eiges
et al. developed an embryonic stem
cell line that was shown to contain
the full mutation of FMR1 with CGG re-
peats up to 1000 triplets. They dem-
onstrate that as a pluripotent undiffer-
entiated stem line, the FMR1 gene is
unmethylated and transcriptionally
active. When differentiated as either
embryoid bodies or as teratomas,
transcription of FMR1 is nearly elimi-007 Elsevier Inc.nated. While the embryoid bodies
show a substantial increase in FMR1
DNA methylation, like cells derived
from fragile X patients, the teratoma-
derived cells show only a modest
increase in CpG methyation. Impor-
tantly, chromatin immunoprecipitation
shows, in both types of differentiated
cells, the epigenetic switch of histone
H3 deacetylation and histone H3K9
methylation. Thus, Eiges et al. argue
that FMR1 inactivation is initiated by
chromatin modifications prior to DNA
methylation. While this conclusion
is certainly in line with work in other
systems indicating DNA methylation
serves as a subsequent transcriptional
lock following heterochromatization
(Feldman et al., 2006), further work
will be required to firmly establish this
temporal pathway of FMR1 inactiva-
tion following differentiation.
What is the importance of the work
by Eiges et al.? Simply put, it is the de-
velopment of a cellular system that, for
the first time, allows experimental in-
sight into the mechanism of FMR1 in-
activation in fragile X syndrome. What
makes FMR1 gene inactivation spe-
cial? It is a unique example in which
epigenetic modification is in response
to genomic modification. Here, expan-
sion of the FMR1 CGG repeat beyond
200 triplets leads to a nearly complete
shift from a euchromatic locus to one
heavily heterochromatized and inacti-
vated. This epigenetic change is local
to the expanded CGG repeat, with his-
tone modifications flanking 50 kb
on either side of the repeat (Gheldof
et al., 2006). The mechanism behind
this process is not at all clear. Eiges
et al. now demonstrate that the FMR1
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differentiated stem cells, and thus the
FMR1 transcript will contain extremely
long CGG repeats. Handa et al. (2003)
demonstrated previously that CGG re-
peats on the FMR1 transcript form
hairpins recognized as Dicer sub-
strates, producing small RNA prod-
ucts. Together, these data suggesta
mechanism for FMR1 silencing. As
postulated earlier by Jin et al. (2004),
a mechanism similar to RNA-induced
initiator of transcriptional gene silenc-
ing (RITS) in lower organisms, may re-
cruit histone modifying activities to
a specific genomic loci, the FMR1 re-
peat in this case, based upon se-
quence homology (Verdel et al.,
2004). Thus, CGG repeat siRNA-like
transcripts could recruit histone meth-
yltransferase(s) to the expanded FMR1
repeat and, following differentiation,
result in transcriptional repression.
Now, based upon the work of Eiges
et al., one can directly test this hypoth-
esis, perhaps by knocking down es-
sential RITS components such as
Argonaute prior to differentiation.
Finally, the disease-specific cell line
developed by Eiges and colleagues
provides a tool to tackle one of the lon-gest-standing questions regarding
fragile X syndrome: the nature of the
fragile site itself. Fragile sites are
locus-specific nonstaining gaps in
metaphase chromosomes. In fragile X
syndrome, the expression of the X
chromosome fragile site at band
Xq27.3, where FMR1 resides, is re-
stricted to cells from individuals carry-
ing the full mutation. Indeed, the very
name of the syndrome is derived
from this relationship. Is the repeat it-
self responsible for the cytological
fragile site, or are the subsequent
DNA methylation and/or histone mod-
ifications at FMR1 required? A simple
karyotypic examination, under the
appropriate culture conditions, is now
attainable and may easily answer this
question as well. Federally funded in-
vestigators in the United States, who
by law are limited in their capacity to
carry out experiments similar to Eiges
et al., can now, at least vicariously,
learn of new insights into fragile X syn-
drome and its unique example of epi-
genetic modification. These results
represent a powerful proof of principle
and indicate the value of generating
disease-specific cell lines based on
PIGD of human embryos.Cell Stem Cell 1,REFERENCES
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